9913 in stock
Noventra Pharma Tirzepatide 30mg | Mounjaro Alternative Pen South Africa
R2050,00
Noventra Pharma Tirzepatide 30mg - GLP-1 agonist proven for weight loss. Appetite suppression, fat loss & metabolic support. Lab-tested, fast SA delivery.
Description
Tirzepatide 30mg Pre-filled Pen
Dual GLP-1 & GIP Receptor Agonist | Multi-Dose Weight Loss Injection
🎯 Benefits | Why Choose Our Pre-filled Pen
💊 Pharmaceutical Grade
Lab-tested for maximum potency and safety assurance.
⚡ Rapid Weight Loss
GLP-1 agonist proven to suppress appetite and accelerate fat burning.
🚚 Fast SA Delivery
Express delivery across South Africa with discrete packaging.
Clinical Indications
- ✓ Type 2 Diabetes Management: Enhanced blood glucose control and HbA1c reduction
- ✓ Obesity Treatment: Significant weight reduction (10-15% body weight)
- ✓ Cardiovascular Protection: Reduced risk of heart disease and stroke
- ✓ Metabolic Syndrome: Improved insulin sensitivity and lipid profiles
How Works | Mechanism of Action
GLP-1 Receptor Activation
binds to GLP-1 receptors, triggering insulin release and glucose regulation.
Appetite Suppression
Slows gastric emptying and increases satiety, leading to reduced caloric intake.
Metabolic Enhancement
Improves insulin sensitivity and promotes fat oxidation for sustained weight loss.
Usage Protocol
Week 1-4
Start: 3.75mg weekly
Week 5-8
Increase: 7.5mg weekly
Maintenance
Target: 7.5mg weekly
Technical Specifications |
Concentration:
30mg Tirzepatide per pen
Volume:
3ml multi-dose
Storage:
2-8°C refrigerated
Manufacturer:
Noventra Pharma
⚕️ Professional Healthcare Notice
This pre-filled pen is intended for use under medical supervision. Consult your healthcare provider before use. Not suitable for type 1 diabetes or diabetic ketoacidosis.
Related products
You may also like these popular picks! Explore our related products and find more styles you’ll love
-
Noventra Pharma Deadpool Stack Pen 20mg | TB-500 + BPC-157 + KPV Recovery SA
R1900,00Original price was: R1900,00.R1800,00Current price is: R1800,00.













